Atlas market file · Equity · United States
Candel Therapeutics, Inc.CADL
- Last close
- 10.58
- Change
- +1.15%
- 96-bar range
- 4.44 – 11.36
- As of
- 6 Aug 2026
Candel Therapeutics, Inc. is a biological products, (no diagnostic substances) issuer listed as CADL on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
CADL
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+86.27% over the window).
Source rail: Yahoo Finance chart API (CADL). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for CADL. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
CADL public profile
Biological products, (no diagnostic substances) issuer. Candel Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
Candel Therapeutics, Inc. trades as CADL on NASDAQ. Candel Therapeutics, Inc. (CADL) has a latest verified close of 10.58, up 1.15%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files CADL under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Candel Therapeutics, Inc. today
Candel Therapeutics (CADL) reported a net loss of $8.9M and negative operating cash flow of $18M in Q1 2026, despite holding $194.8M in cash. The biotech firm’s financials contrast with its promotional narrative of advancing viral immunotherapies for solid tumors, including FDA-regenerative medicine status for CAN-2409.
Candel’s operations revolve around two investigational therapies: aglatimagene besadenovec and linoserpaturev. Its official pipeline emphasizes clinical trials for solid tumors, yet the 10-Q filing reveals no revenue and $9.8M spent on R&D. The company’s May 2026 press release highlighted 'favorable trends' in Phase 3 trials but provided no concrete revenue pathway, leaving investors reliant on trial outcomes for future value.
Key financial risks include sustained cash burn, with $675K spent on capex and a diluted share count of 62.4M. While the FDA designation for CAN-2409 offers potential, Candel’s reliance on clinical progress without commercial revenue exposes it to funding and regulatory uncertainties. (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1841387/000190968026000002/xslF345X06/ownership.xml)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
CADL technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on CADL
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep CADL research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
CADL FAQ
What is Candel Therapeutics, Inc. (CADL)?Candel Therapeutics, Inc. (CADL) has a latest verified close of 10.58, up 1.15%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Candel Therapeutics, Inc. (CADL) has a latest verified close of 10.58, up 1.15%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for CADL?Candel Therapeutics, Inc. (CADL) has a latest verified close of 10.58, up 1.15%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Candel Therapeutics, Inc. (CADL) has a latest verified close of 10.58, up 1.15%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files CADL under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the CADL page updated?The CADL public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The CADL public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for CADL?The CADL file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CADL. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The CADL file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CADL. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on CADL?Yes. The workstation can open CADL, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open CADL, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this CADL page investment advice?No. The CADL page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The CADL page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →